期刊文献+

卵巢癌复发预测研究进展 被引量:5

Advances in ovarian cancer recurrence prediction
下载PDF
导出
摘要 卵巢癌死亡率仍居妇科肿瘤之首。治疗后的复发是影响卵巢癌患者存活率的重要因素。有效的复发预测因子的发现与机制研究将为卵巢癌复发控制提供思路,而复发的早期诊断和干预则能够有效延长卵巢癌患者的生存时间。因此首次治疗后有关卵巢癌复发风险的有效预测和复发的早期诊断,已经成为业内关注的热点。本文就该领域的研究进展进行分析和探讨。 Ovarian cancer mortality remains head of gynecologic tumor. After treatment of the recurrence in patients with ovarian cancer survival rates are important factors. Effective relapse predictors of discovery and mechanism study for recurrent ovarian cancer control provides train of thought, and the recurrence of early diagnosis and intervention can effectively prolong the survival time of patients with ovarian cancer. Therefore, after first treatment for ovarian cancer recurrence risk effective prediction and early diagnosis of recurrence, the industry has become the focus of attention. In this paper, the research progress of this area are analyzed and discussed.
作者 吴鹏 郑智国
出处 《中国现代医生》 2012年第4期29-30,33,共3页 China Modern Doctor
基金 2008年度浙江省自然科学基金课题(Y2080586)
关键词 卵巢癌 复发预测 复发早期诊断 Ovarian cancer Relapse predicting Early diagnosis of relapse
  • 相关文献

参考文献25

  • 1Engel J,Eckel R,Schubert-Fritschle G,et al. Moderate progress for o- varian cancer in the last 20 years:prolongation of survival,but no im- provement in the cure rate[J]. Eur J Cancer,2002,38(18):2435-2445.
  • 2Herzog TJ,Pothuri B. Ovarian cancer:a focus on management of recur- rent disease[J]. Nat Clin Pract Onco1,2006,3 (11 ):604-611.
  • 3Tanner EJ,Chi DS,Eisenhauer EL,et al. Surveillance for the detection of recurrent ovarian cancer:survival impact or lead-time bias? [J]. Gynecol Oncol,2010,117(2) :336-340.
  • 4Kim K,Ryu Sy. Major clinical research advances in gynecologic cancer 2009[J]. J Gynecol Oncol,2009,20.(4):203-209.
  • 5Bakkum-Gamez JN,Richardson DL,Seamon LG,et al. Influence of in- traoperative capsule rupture on outcomes in stage 1 epithelial ovarian cancer[J]. Obstet Gynecol 2009 113 ( 1 ) : 11-17.
  • 6Lenhard SM,Bufe A,Kumper C,et al. Relapse and survival in early- stage ovarian cancer[J]. Arch Gynecol Obstet ,2009,280( 1 ):71-77.
  • 7Chan JK,Tian C, Monk BJ,et al. Prognostic factors for high-risk early- stage epithelial ovarian cancer:a Gynecologic Oncology Group study[J]. Cancer, 2008,112 (10) : 2202-2210.
  • 8Kang WD,Choi HS,Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer[J]. Gynecol Oncol, 2010,116( 1 ) :57-60.
  • 9Winter WE 3rd,Maxwell GL,Tian C,et al. Prognostic factors for stage III epithelial ovarian cancer:a gynecologic oncology group study[J]. J Clin On col, 2007,25 ( 24 ): 3621-3627.
  • 10Riedinger JM,Eche N,Basuyau JP,et al. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy:a French multicentric study[J]. Gynecol Oncol,2008,109 (2) : 194--198.

同被引文献60

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部